USA & Canada
Aspen Pharmacare Canada was founded in 2014 to support our products distributed in this region. The development of our complex API capabilities into niche FDF offerings represents an opportunity for future product launches in the United States. Our satellite API facility in Sioux City supports the Oss site in supplying APIs worldwide.
Contribution to Group revenue
Revenue contribution - by therapeutic category
- The Canadian pharmaceutical sector is estimated to grow 4,9% to USD28,4 billion in 2018.
- The US pharmaceutical sector continues to be the world’s largest and growth is expected to average 6% to 9% through to 2021.
Source: June 2017 IMS
Number of products launched:
IMS value of pipeline as at 30 June 2017 anticipated to be launched in:
0 – 2 years
3 – 5 years
USD1 671 million
Number of product recalls:
Average staff turnover:
Number of work-related fatalities:
Number of permanent employees:
|Revenue – R’billion||2017||2016 (CER)*||% change|
|High Potency & Cytotoxics||0,3||0,4||(20)|
|Other Commercial Pharmaceutical Brands||0,5||0,1||>100|
* Constant exchange rate: FY16 restated at FY17 average exchange rates. Note: Commercial Pharmaceuticals revenue by customer geography and manufacturing revenue by place of manufacture.